

Medical treatment for urogenital tuberculosis (UGTB)

Christian Wejse¹

¹Department of Infectious Diseases/Center for Global Health, Dept of Public Health, Aarhus University, Aarhus University Hospital, -, Denmark

Abstract

Urogenital tuberculosis (UGTB) should in general be treated as pulmonary TB with a four-drug regimen of Isoniazid, Rifampicin, Ethambutol and Pyrazinamide for a total of 6 months, Ethambutol and Pyrazinamide only the first two months. Some patients may need longer treatment (cavitary disease, kidney abscess/malfunction, HIV co-infection). Treatment of multi-drug resistant tuberculosis (MDR-TB) requires use of long-term intravenous treatment with aminoglycosides and other drugs with considerable toxicity for 18–24 months. Complications such as urinary tract obstruction may occur and should be treated with corticosteroids or surgery.

Medical treatment

Treatment of UGTB is in general similar to treatment for pulmonary TB. Treatment according to WHO guidelines with four drugs is used: Isoniazid (INH), Rifampicin (RIF), Ethambutol (ETH) and Pyrazinamide (PYR) as displayed in Table 1 and Table 2. Standard treatment duration is two months of intensive phase with all four drugs daily, followed by 4 or 7 months of continuation phase with only two drugs (INH+RIF), in total 6–9 months. Appropriate treatment with standard antituberculous agents for six months is usually successful in eradicating active UGTB, provided that it is drug-susceptible TB [1], and this is the general recommended duration of treatment [2], [3]. The 4-month continuation phase should therefore be used in the large majority of patients, the 7-month continuation phase should be reserved only for special groups of patients, such as patients with cavitary pulmonary TB with a positive sputum culture after the initial 2-month treatment. TB is often a multiorgan disease, and in case of involvement of CNS or bone/joint, treatment should be prolonged to 12 months. This may also be useful in cases with extensive soft-tissue involvement [4]. In particular patients with major kidney involvement and abscess or compromised renal function may need prolonged treatment for 9–12 months. In case of concomitant HIV infection, TB treatment may also be prolonged in particular if the patient is severely immunocompromised, and HIV testing is obligatory prior to any initiation of antituberculous treatment. Some forms of anti-retroviral treatment (ART) for HIV will require modifications in the TB treatment regimen such as replacement of Rifampicin with Rifabutin. In case of concomitant HIV infection, an infectious disease specialist should be consulted for initiation of ART, and combining ART with the necessary TB treatment is a task for a specialist because of several interactions, and this is not outlined here.

Table 1: Treatment regimen for UGTB

Initial 2 months

Isoniazid (INH)	300 mg
Rifampicin* (RIF)	600 mg
Ethambutol (ETH)	1,200 mg
Pyrazinamide (PYR)	2,000 mg
Pyridoxine/B-combin F	20 mg per day or 50 mg every 2nd day

Four-drug combination treatment may be used if available to reduce the pill-burden; e.g. the widely used Rimstar which contains isoniazid, rifampicin, ethambutol and pyrazinamide.

Weight (kg)	30–39	40–54	55–70	>70
Daily tablets of Rimstar	2	3	4	5

Continuation phase the following 4 months

Isoniazid	300 mg
Rifampicin*	600 mg
Pyridoxine	20 mg per day or 50 mg every 2nd day

*Rifampicin should be taken fasting, preferably half an hour before a meal.

Table 2: Dose-reduction according to weight (adults <50 kg)

	Weight 30–40 kg	Weight 40–50 kg
Isoniazid	300 mg	300 mg
Rifampicin	450 mg	450 mg
Ethambutol	600 mg	800 mg
Pyrazinamide	1,000 mg	1,500 mg

Treatment of multi-drug resistant tuberculosis

Treatment of multi-drug resistant tuberculosis (MDR-TB) defined as resistance to both RIF and INH is a particular difficult issue, requiring use of toxic and perhaps very expensive drugs. MDR-TB constitutes globally 3.9% of new TB cases and 21% of previously treated cases [5], this equals to 580,000 new cases annually and an estimated 250,000 deaths from MDR-TB [5], unfortunately only 20% of those in need of MDR-TB treatment are enrolled on an MDR-TB treatment program. It is very important that all patients undergoing TB treatment have had samples sent for TB culture prior to treatment in order to be able to do resistance testing.

In case of multi-drug resistance, the treatment should include the use of at least five drugs assumed to be effective, preferably documented through drug susceptibility tests. Treatment of MDR-TB is very complicated and has a duration of up to two years. In case of drug resistance, an infectious disease specialist with experience in MDR-TB treatment should be consulted, as it is generally kept on few hands because of the considerable toxicity of the drugs. Briefly the main aspects of MDR-TB treatment are outlined here, as MDR-TB constitutes up to 30% of new TB cases and 70% of re-treatment cases in some countries in Eastern Europe [6]. Treatment of MDR-TB may therefore be a very common issue faced in UGTB treatment in some areas. If possible, an expert consilium should be consulted [7]. Globally, only 50% of all MDR-TB cases are successfully treated [5]. If an MDR-TB case is not successfully treated, there is a risk of progression to XDR-TB (extensively drug resistant TB) which means additional resistance to aminoglycosides and fluoroquinolones. These patients are even more difficult to treat, hence expert consultations for treatment is obligatory. XDR-TB has been reported in 117 countries and an estimated 9.5% of all patients with MDR-TB have XDR-TB [5].

The main concept in treatment of MDR-TB [8] is to use an injectable agent such as amikacin, kanamycin, or capreomycin (streptomycin is usually not used because of high rates of resistance), a fluoroquinolone (levofloxacin, moxifloxacin or gatifloxacin are recommended), and at least three other agents with probable activity (ethionamide or prothionamide, cycloserine, para-aminosalicylic acid). First line agents (PYR and ETH) with retained activity should also be used. Patients with MDR-TB require a regimen with at least five effective TB medicines during the intensive phase; PYR and four core second-line TB drugs (see Table 3) – one each from Group A and Group B, and at least two from Group C [9], [10].

Table 3: Reduced kidney function (creatinin clearance <30 ml/min); dose-reduction, adults

Isoniazid	300 mg x 1 daily (150 mg if clearance <10 ml/min and ÷ dialysis)
Rifampicin	600 mg x 1 daily
Ethambutol	15–25 mg/kg x 3 per week (avoid if no dialysis)
Pyrazinamide	1,500 mg/(25–30 mg/kg) x 3 per week

In case of haemodialysis: Antituberculous treatment should be given AFTER dialysis

Ideally the injectable agent is administered daily for the first 6–8 months, forming an “intensive phase” of treatment, with the other drugs then continued, forming a “continuation phase” which should last an additional 12–16 months. There is a short course treatment recommended for selected cases, but since extra-pulmonary TB patients are never considered for this, it does not apply to UGTB patients [10]. Very often, adverse effects (nephro- and ototoxicity) will require ceasing treatment with the injectable agent, but it is often possible to manage side effects through dose reduction to 3 times weekly or swapping drugs for remaining alternatives.

In patients with MDR-TB, surgery may also be used as a means to reduce the amount of lung tissue with intractable pathology, to reduce bacterial load and thus improve prognosis [11]. WHO now recommends elective partial lung resection (lobectomy or wedge resection) alongside a recommended MDR-TB regimen [10].

Treatment variations according to species

UGTB is usually caused by *Mycobacterium tuberculosis* or (in particular in West Africa) by *Mycobacterium africanum*. However, *Mycobacterium bovis* is also part of the *Mycobacterium tuberculosis* complex and may be seen in UGTB, in particular among elderly patients. Non-tuberculous mycobacteria are rare causes of urinary tract disease, and are not considered here. *M. bovis* is inherently resistant to PYR. This should therefore be avoided in such cases, and could be replaced with a flouoroquinolone.

Renal impairment

In case of renal insufficiency, drug dose adjustments are required for ETH and PYR as these drugs are cleared in the kidneys, INH and RIF can safely be used without dosing adjustments, even in end-stage renal disease. Dose-adjustments are made according to Glomerular Filtration Rate (GFR), as shown in Table 4. For these particular cases, monitoring plasma drug-concentrations is useful if available. PYR may induce hyperuricaemia and hyperuricuria (which may also be used to monitor treatment adherence) but could therefore be harmful in case of urinary tract damages. In such cases, a xanthine oxydase inhibitor (Allopurinol) could be added [12].

Table 4: Drugs used for treatment of multi-drug resistant tuberculosis (MDR-TB)

	Name of drug	Abbreviation
	Levofloxacin	Lfx
A. Fluoroquinolones	Moxifloxacin	Mfx
	Gatifloxacin	Gfx
	Amikacin	Am
	Capreomycin	Cm
B. Second-line injectable agents	Kanamycin	Km
	(Streptomycin)	(S)

	Name of drug	Abbreviation
	Ethionamide/Prothionamide	Eto/Pto
C. Other core second-line agents	Cycloserine/Terizidone	Cs/Trd
	Linezolid	Lzd
	Clofazimine	Cfz
	Pyrazinamide	Z
D. Add-on agents (not part of the core MDR-TB regimen)	D1 Ethambutol	E
	High-dose isoniazid	Hh
	Bedaquiline	Bdq
	D2 Delamanid	Dlm
	p-aminosalicylic acid	PAS
	Imipenem-cilastatin	lpm
	D3 Meropenem	Mpm
	Amoxicillin-clavulanate	Amx-Clv
	(Thioacetazone)	T

Treatment response

The clinical response to antituberculous treatment is usually excellent because of high urinary concentrations of antituberculous drugs and good renal vascular supply. Sterilization of mycobacteria in urine usually occurs within two weeks after treatment start. Yet, there is often a considerable mortality, just as in TB disease in other organs. This is mostly because of late presentation or co-morbidity, and the overall TB mortality in 2015 was 14.5% [5]. In a UGTB cohort from Thailand the mortality was 26%, with age, comorbidity and no treatment being the major risk factors [13]. In other cohorts, mortality as low as 1% has been reported [14]. Relapse of TB is rare in culture-confirmed urinary tract disease treated with standard therapy [15], even among patients who require nephrectomy [16]. There are also some reports of high relapse rates, up to 20% in Turkey [17], [18], but historical cohorts with long follow-up >10 years indicate that cure rates of close to 100% are generally to be expected on current treatment regimens [19].

Complications during treatment

During antituberculous therapy upper urinary tract obstruction (UTO) may occur [20]. Signs and symptoms of UTO should be monitored (flank pain, renal colic, hydronephrosis) in order to detect this debilitating condition, which may occur in the first few weeks of antituberculous therapy. It may be interpreted as a form of paradoxical reaction to treatment, which is often seen in TB, in particular but not only among HIV-infected in combination with initiating antiretroviral therapy [2], [21]. It is caused by inflammation, followed by fibrosis and obstruction of the collecting system [16]. Ureteral strictures may be caused by the disease process prior to treatment, but may also progress during treatment due to scarring and subsequent narrowing of the lumen [3]. Usually, this is occurring within the first two months of treatment [22]. Fibrosis of the bladder wall with reduced capacity is seen in 9% of patients [16]. In severe and neglected cases, bladder contractions may even develop [23].

Treatment of complications

The treatment for obstruction and other manifestations of paradoxical reaction may primarily be surgical and contractions may need major surgical reconstruction [23]. Some reports indicate a very frequent need for surgery, up to 32% of male cases with UGTB in a large India cohort [4]. When urinary tract obstructions occur, anti-tuberculous treatment is not always sufficient, and reconstructive surgery may be

indicated [3]. When UGTB has led to major kidney lesions such as caverns, surgical intervention is indicated in advanced cases [24]. All surgical interventions should be performed under the coverage of anti-TB therapy. Adding corticosteroid treatment may be considered in particular in minor strictures, e.g. prednisolon 50 mg daily with gradual rundown over weeks. Supplementary treatment with corticosteroids is not generally recommended in UGTB [2], but there is no reason to fear adding corticosteroids, once the patient is on effective treatment. This will not put the patient at increased risk of disseminated disease and corticosteroid as adjunctive therapy is increasingly used even in pulmonary TB [25].

Note

This chapter was primarily published in the journal *GMS Infectious Diseases* [26].

References

1. Gow JG, Barbosa S. Genitourinary tuberculosis. A study of 1117 cases over a period of 34 years. *Br J Urol.* 1984 Oct;56(5):449-55.
2. Cek M, Lenk S, Naber KG, Bishop MC, Johansen TE, Botto H, Grabe M, Lobel B, Redorta JP, Tenke P; Members of the Urinary Tract Infection (UTI) Working Group of the European Association of Urology (EAU) Guidelines Office. EAU guidelines for the management of genitourinary tuberculosis. *Eur Urol.* 2005 Sep;48(3):353-62. DOI: [10.1016/j.eururo.2005.03.008](https://doi.org/10.1016/j.eururo.2005.03.008)
3. Kulchavenya E, Naber K, Bjerklund Johansen TE. Urogenital Tuberculosis: Classification, Diagnosis, and Treatment. *Eur Urol Suppl.* 2016 Jul;15(4):112–21. DOI: [10.1016/j.eursup.2016.04.001](https://doi.org/10.1016/j.eursup.2016.04.001)
4. Chandra S, Chandra H, Chauhan N, Gaur DS, Gupta H, Pathak VP, Burathoki SK. Male genitourinary tuberculosis – 13 years experience at a tertiary care center in India. *Southeast Asian J Trop Med Public Health.* 2012 Mar;43(2):364-9.
5. World Health Organization. Global tuberculosis report 2017. Geneva: World Health Organization; 2017. Available from: http://www.who.int/tb/publications/global_report/en/
6. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2017. Stockholm: European Centre for Disease Prevention and Control; 2017. Available from: <https://ecdc.europa.eu/sites/portal/files/documents/ecdc-tuberculosis-surveillance-monitoring-Europe-2017-WEB.pdf>
7. D'Ambrosio L, Tadolini M, Dupasquier S, Tiberi S, Centis R, Dara M, Blasi F, Migliori GB. ERS/WHO tuberculosis consilium: reporting of the initial 10 cases. *Eur Respir J.* 2014 Jan;43(1):286-9. DOI: [10.1183/09031936.00125813](https://doi.org/10.1183/09031936.00125813)
8. Millard J, Ugarte-Gil C, Moore DA. Multidrug resistant tuberculosis. *BMJ.* 2015 Feb;350:h882.
9. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization; 2014. Available from: http://www.who.int/tb/publications/pmdt_companionhandbook/en/
10. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis; 2016 update; October 2016 revision. Geneva: World Health Organization; 2016. Available from: <http://www.who.int/tb/areas-of-work/drug-resistant-tb/treatment/resources/en/>
11. Fox GJ, Mitnick CD, Benedetti A, Chan ED, Becerra M, Chiang CY, Keshavjee S, Koh WJ, Shiraishi Y, Viiklepp P, Yim JJ, Pasvol G, Robert J, Shim TS, Shin SS, Menzies D; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis. *Clin Infect Dis.* 2016 Apr;62(7):887-95. DOI: [10.1093/cid/ciw002](https://doi.org/10.1093/cid/ciw002)
12. Naftalin CM, Verma R, Gurumurthy M, Lu Q, Zimmerman M, Yeo BCM, Tan KH, Lin W, Yu B, Dartois V, Paton NI. Coadministration of allopurinol to increase antimycobacterial efficacy of pyrazinamide as evaluated in a whole-blood bactericidal activity model. *Antimicrob Agents Chemother.* 2017 Oct;61(10):e00482-17. DOI: [10.1128/AAC.00482-17](https://doi.org/10.1128/AAC.00482-17)
13. Hsu HL, Lai CC, Yu MC, Yu FL, Lee JC, Chou CH, Tan CK, Yang PC, Hsueh PR. Clinical and microbiological characteristics of urine culture-confirmed genitourinary tuberculosis at medical centers in Taiwan from 1995 to 2007. *Eur J Clin Microbiol Infect Dis.* 2011 Mar;30(3):319-26. DOI: [10.1007/s10096-010-1083-z](https://doi.org/10.1007/s10096-010-1083-z)
14. Altıparmak MR, Trabulus S, Balkan II, Yalin SF, Denizli N, Aslan G, Doruk HE, Engin A, Tekin R, Birengel S, Cetin BD, Arslan F, Turhan V, Mert A. Urinary tuberculosis: a cohort of 79 adult cases.

- Ren Fail. 2015 Aug;37(7):1157-63. DOI: [10.3109/0886022X.2015.1057460](https://doi.org/10.3109/0886022X.2015.1057460)
15. Weir MR, Thornton GF. Extrapulmonary tuberculosis. Experience of a community hospital and review of the literature. *Am J Med.* 1985 Oct;79(4):467-78. DOI: [10.1016/0002-9343\(85\)90034-8](https://doi.org/10.1016/0002-9343(85)90034-8)
 16. Figueiredo AA, Lucon AM. Urogenital tuberculosis: update and review of 8961 cases from the world literature. *Rev Urol.* 2008;10(3):207-17.
 17. Gokalp A, Gultekin EY, Ozdamar S. Genito-urinary tuberculosis: a review of 83 cases. *Br J Clin Pract.* 1990 Dec;44(12):599-600.
 18. Gokce G, Kilicarslan H, Ayan S, Tas F, Akar R, Kaya K, Gultekin EY. Genitourinary tuberculosis: a review of 174 cases. *Scand J Infect Dis.* 2002;34(5):338-40.
 19. Gow JG. Results of treatment in a large series of cases of genito-urinary tuberculosis and the changing pattern of the disease. *Br J Urol.* 1970 Dec;42(6):647-55.
 20. Psihramis KE, Donahoe PK. Primary Genitourinary Tuberculosis: Rapid Progression and Tissue Destruction During Treatment. *J Urol.* 1986 May;135(5):1033-6. DOI: [10.1016/S0022-5347\(17\)45970-2](https://doi.org/10.1016/S0022-5347(17)45970-2)
 21. Bell LC, Breen R, Miller RF, Noursadeghi M, Lipman M. Paradoxical reactions and immune reconstitution inflammatory syndrome in tuberculosis. *Int J Infect Dis.* 2015 Mar;32:39-45. DOI: [10.1016/j.ijid.2014.12.030](https://doi.org/10.1016/j.ijid.2014.12.030)
 22. Shin KY, Park HJ, Lee JJ, Park HY, Woo YN, Lee TY. Role of early endourologic management of tuberculous ureteral strictures. *J Endourol.* 2002 Dec;16(10):755-8. DOI: [10.1089/08927790260472917](https://doi.org/10.1089/08927790260472917)
 23. Singh V, Sinha RJ, Sankhwar SN, Sinha SM. Reconstructive surgery for tuberculous contracted bladder: experience of a center in northern India. *Int Urol Nephrol.* 2011 Jun;43(2):423-30. DOI: [10.1007/s11255-010-9815-7](https://doi.org/10.1007/s11255-010-9815-7)
 24. Kulchavenya E. *Current Therapy and Surgery for Urogenital Tuberculosis.* Switzerland: Springer International Publishing; 2016.
 25. Critchley JA, Orton LC, Pearson F. Adjunctive steroid therapy for managing pulmonary tuberculosis. *Cochrane Database Syst Rev.* 2014 Nov 12;(11):CD011370. DOI: [10.1002/14651858.CD011370](https://doi.org/10.1002/14651858.CD011370)
 26. Wejse C. Medical treatment for urogenital tuberculosis (UGTB). *GMS Infect Dis.* 2018;6:Doc04. DOI: [10.3205/id000039](https://doi.org/10.3205/id000039)

Corresponding authors: Assoc. Prof. Christian Wejse, Aarhus University, Aarhus University Hospital, Department of Infectious Diseases/Center for Global Health, Dept of Public Health, - -, Denmark, Phone: -, E-mail: wejse@dadlnet.dk

Citation note: Wejse C. Medical treatment for urogenital tuberculosis (UGTB). Version: 2018-08-09. In: Bjerklund Johansen TE, Wagenlehner FME, Matsumoto T, Cho YH, Krieger JN, Shoskes D, Naber KG, editors. *Urogenital Infections and Inflammations.* Berlin: German Medical Science GMS Publishing House; 2017-. DOI: [10.5680/lhuiu000037](https://doi.org/10.5680/lhuiu000037)

Copyright: © 2025 Christian Wejse

This is an Open Access publication distributed under the terms of the Creative Commons Attribution 4.0 International License. See license information at <https://creativecommons.org/licenses/by/4.0/>